Coromandel International Limited Intrinsic Value

COROMANDEL · Chemicals · Current price ₹1,755

Full stock page
DocStoX fair value
₹2,534
medium confidence · 54/100
Current price
₹1,929
Upside to fair value
+31.4%
Estimate range
₹2,281 – ₹2,788
Quality score
4.5 / 10
Model it yourself — Intrinsic Value Calculator
Opens pre-filled with Coromandel International Limited's latest numbers.

Is Coromandel International Limited undervalued?

We estimate the fair value of Coromandel International Limited at ₹2,534 per share, against a market price of ₹1,929. That puts the share price about +31.4% below our estimate, at medium confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.

How this fair value is calculated

This estimate comes from 2 methods: Normalized earnings (mid-cycle EV/EBITDA) (₹2,702), Fair multiple (P/E) (₹1,563). Each is weighted by how well its inputs held up for this company. The full working, including the assumptions and what data was missing, is set out below.

The range around this estimate

Our estimate for Coromandel International Limited spans ₹2,281 to ₹2,788. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.

Margin of safety

Value investors look for a margin of safety: a discount to estimated value that absorbs being wrong. At ₹1,929 against an estimated value of ₹2,534, Coromandel International Limited trades at +31.4%, i.e. a discount to our estimate. How much margin to demand depends on how much you trust the inputs, which is what the confidence band below is for.

How we got this fair value

Every number below is part of the same estimate for Coromandel International Limited. Nothing here is a target price or a forecast of where the share price will go.

Medium confidence54/100

Workable, with real gaps. Weigh it alongside your own view rather than on its own.

Estimate range ₹2,281 – ₹2,788

Why this method for this business

Normalized earnings and EV/EBITDA are the most appropriate models for a cyclical chemical business like Coromandel, which requires mid-cycle earnings normalization and a through-cycle valuation multiple.

The models behind the number

Each method is weighted by how well its inputs held up for this company.

Normalized earnings (mid-cycle EV/EBITDA)
₹2,70260% weight

Cyclical valued off mid-cycle earnings and a through-cycle EV/EBITDA (§6.6)

Fair multiple (P/E)
₹1,56310% weight
EV / EBITDA(not enough data)

required inputs missing

  • Relative PE is less relevant for a cyclical business where trailing P/E can be misleading at cycle peaks or troughs
  • DCF is not suitable for a commodity-based business with volatile cash flows

What was missing

  • Lack of forward EPS estimates for precise normalization
  • Limited analyst coverage for sector multiple validation

What drives it

22 inputs, grouped by how strong each claim is
ReportedRead from filings or market data. Verifiable, not our opinion.
Revenue (TTM)
31,480 ₹ cr

computed

Net debt
1,434.7 ₹ cr

computed

Shares outstanding
29,50,94,007

computed

Sector-median P/E
17.13×

peer-median

Peers used
7

peer-median

EPS (TTM)
62.11 ₹/share

computed

Own-history median P/E
17.1×

reconstructed (one feature, dampened — not a cap)

AssumptionA forward input the model chose. Reasonable people can disagree here.
EBITDA margin (cycle median)
11%

computed (≤5y median)

Through-cycle EV/EBITDA
23.44×

own-history (median of 5y)

JudgementOur read of the evidence, not a measurement.
Term: quality
+6.7%

quality 68/100 (high, stable returns) → premium

Term: growth
+17.3%

durable ~12% CAGR (ROCE 23% > hurdle) → premium

Term: capital_allocation
+7.2%

capital allocation: rising ROCE funded by strong FCF → premium

Term: financial_strength
+8.3%

financial strength: effectively debt-free → premium

Term: history
-0.1%

history: market paid -0% vs sector, dampened ×0.3 (one feature, not the anchor)

Term: sector_rerating
+0.0%

sector re-rating: no sector-norm history → not used

Term: rate_regime
+1.2%

rates: risk-free 6.9% below ~7.1% normal → higher multiple

Term: risk
+0.0%

risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)

DerivedFalls out of the inputs above: a model output, not an independent input.
Mid-cycle EBITDA
3,462.8 ₹ cr

computed

Enterprise value
81,161.1 ₹ cr

computed

Premium vs sector
+46.9%

fundamentals + macro (not capped at own history)

Fair-multiple confidence
85%

data completeness + term agreement

Fair P/E
25.16×

sector median × ∏(1+term) — Dynamic Fair Multiple

Who computed this

A language model (qwen3:8b) selects the valuation method and the judgement inputs for Coromandel International Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.

Estimated 14 Sept 2026. Re-run as new financials and news arrive.

How we value stocks

We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.

Read the full fair-value methodology

More on Coromandel International Limited

DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.